Csl Limited

The University of Melbourne

Csl Limited, A.c.n.

Bruce Carter Ross

Ian George Barr

Elizabeth Ann Webb

Linda J Rothel

Dianna M Hocking

Michelle A Patterson

Catherine T Agius

Mai B Margetts

Larissa Czajkowski

Mai Brigid Margetts

Linda Joy Rothel

Catherine Therese Agius

Michelle Anne Patterson

The present invention relates to isolatedpolypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 110; SEQ. ID. NO. 111; SEQ. ID. NO. 112; SEQ. ID. NO. 113; SEQ ID NO: 120; SEQ. ID. NO. 123; SEQ. ID. NO. 124; SEQ. ID. NO. 125; SEQ. ID. NO. 130; SEQ. ID. NO. 131; SEQ. ID. NO. 132; SEQ. ID. NO. 133; SEQ. ID. NO. 135; SEQ. ID. NO. 136; SEQ. ID. NO. 137; SEQ. ID. NO. 138; SEQ. ID. NO. 143; SEQ. ID. NO. 144; SEQ. ID. NO. 145; SEQ. ID. NO. 146; SEQ. ID. NO. 147; SEQ. ID. NO. 148; and amino acid sequences at least 95% identical thereto.

[object Object]

The present invention relates to isolatedpolypeptides and nucleotides. The polypeptides include;

The present invention relates to solublepolypeptides derived from PG32 and PG33 and to polynucleotides encoding these polypeptides. Thepolypeptides and nucleotides can be used in compositions for use in raising an immune response in a subject againstand treating or preventing or reducing the severity of the condition known as periodontitis or in other conditions related to infection with

Porphyromonas gingivalis recombinant proteins and truncations

The present invention relates to isolated polynucleotides. The polynucleotides comprises a contiguous sequence of at least 20 nucleotides which is identical to a contiguous sequence of at least 20 nucleotides within a sequence selected from the group consisting of SEQ. ID. NO. 1 to SEQ. ID. NO. 1120 and sequences complementary thereto.

P. gingivalis polynucleotides and uses thereof

Growing community of inventors

Coburg, Australia

Bruce Carter Ross